Onemia® is Acasti’s first product to be marketed to healthcare practitioners and was introduced in the U.S. in 2011. As a medical food, Onemia® is only administered under the supervision of a physician and is intended for the specific dietary management of
Onemia® consists of concentrated omega-3 phospholipids and antioxidants purified from krill oil, at a concentration which is considerably higher than that found in Neptune Krill Oil (NKO®).
Medical foods are a specific class of products under the U.S. Food and Drug Administration (FDA) and are defined by them as: “a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on
The requested URL /c/counter.php was not found on this server.recognized scientific principles, are established by medical evaluation.”
Acasti is positioning Onemia® to be theproduct of choice in a multimillion-dollar market targeting the clinical dietary management of cardiometabolic disorders. Nonclinical studies conducted by Acasti, supported by clinical testing conducted on Neptune Krill Oil (NKO®), have shown Onemia® to be safe and effective for the dietary management of omega-3 phospholipids deficiency and the related abnormal lipid profiles and cardiometabolic disorders. Abnormal lipid profiles can lead to
Not Founda number of conditions including hyperlipidemia (which generally manifests as high LDL (bad cholesterol) and high triglycerides), atherosclerosis (the build-up of plaque on the inside of blood vessels), diabetes, rheumatoid arthritis, and gastroenterology disorders.
Onemia® is now in the early stages ofcommercialization and has begun generating revenues for Acasti. To date, Onemia® has been very well received by physicians and Acasti expects interest to build further as doctor’s confidence in its benefits increases.
Initially, Onemia® is being distributed in the United States by Acasti to physicians, who then can either provide it to their patients directly or via a website by using a dedicated medical food access code. Acasti also makes Onemia® available via distributors and behind-the-counter in pharmacies. In 2012, Acasti entered into an agreement with a medical food distributor in the United States, which is distributing Onemia® through its network of dispensing physicians under its own brand name. Acasti intends to make Onemia® available via additional distributors and behind-the-counter in more pharmacies in the United States and to secure distribution partners to commercialize Onemia® outside of the United States.
Please visit Onemia's official web site : www.onemia.com